Bronchiolitis obliterans syndrome (BOS) is the most common form of CLAD and is characterized by airflow limitation and an obstructive spirometric pattern without high-resolution computed tomography (HRCT) evidence of parenchymal opacities. Computed tomography and microCT analysis show abundant small airway obstruction, starting from the fifth generation of airway branching and affecting up to 40–70% of airways. The pathogenesis of BOS remains unclear. It is a multifactorial syndrome that leads to pathological tissue changes and clinical manifestations. Because BOS is associated with the worst long-term survival in LTx patients, many studies are focused on the early identification of BOS. Markers may be useful for diagnosis and for understan...
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunctio...
Rationale: Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in understanding ...
Lung transplantation (LTx) is the final treatment option for patients suffering from end-stage lung ...
Lung transplantation is the treatment of choice for patients with end-stage lung disease. However, l...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
The main limitation for overall survival after lung transplantation (LTx) is the development of chro...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Introduction: Bronchiolitis obliterans syndrome (BOS) is the most common form of CLAD and is charact...
AbstractBronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with l...
Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival af...
Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreacti...
Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival af...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
Abstract Chronic rejection in the form of bronchiolitis obliterans syndrome (BOS) is the main hindra...
Background: There is a need for non-invasive parameters that are sensitive to the development of the...
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunctio...
Rationale: Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in understanding ...
Lung transplantation (LTx) is the final treatment option for patients suffering from end-stage lung ...
Lung transplantation is the treatment of choice for patients with end-stage lung disease. However, l...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
The main limitation for overall survival after lung transplantation (LTx) is the development of chro...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Introduction: Bronchiolitis obliterans syndrome (BOS) is the most common form of CLAD and is charact...
AbstractBronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with l...
Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival af...
Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreacti...
Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival af...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
Abstract Chronic rejection in the form of bronchiolitis obliterans syndrome (BOS) is the main hindra...
Background: There is a need for non-invasive parameters that are sensitive to the development of the...
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunctio...
Rationale: Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in understanding ...
Lung transplantation (LTx) is the final treatment option for patients suffering from end-stage lung ...